ROCK2 (NM_004850) Human Mass Spec Standard

CAT#: PH317764

ROCK2 MS Standard C13 and N15-labeled recombinant protein (NP_004841)



  View other "ROCK2" proteins (3)

Need it in bulk or customized?
Get a free quote

CNY 19,520.00


货期*
4周

规格
    • 10 ug

Product images

经常一起买 (2)
Transient overexpression lysate of Rho-associated, coiled-coil containing protein kinase 2 (ROCK2)
    • 100 ug

CNY 4,840.00


Anti-ROCK2 Rabbit Polyclonal Antibody
    • 100 ul

CNY 1,999.00
CNY 3,280.00

Specifications

Product Data
Description ROCK2 MS Standard C13 and N15-labeled recombinant protein (NP_004841)
Species Human
Expression Host HEK293
Expression cDNA Clone or AA Sequence RC217764
Predicted MW 160.7 kDa
Protein Sequence
Tag C-Myc/DDK
Purity > 80% as determined by SDS-PAGE and Coomassie blue staining
Concentration >0.05 µg/µL as determined by microplate BCA method
Labeling Method Labeled with [U- 13C6, 15N4]-L-Arginine and [U- 13C6, 15N2]-L-Lysine
Buffer 25 mM Tris-HCl, 100 mM glycine, pH 7.3
Reference Data
RefSeq NP_004841
RefSeq Size 6401
RefSeq ORF 4164
Synonyms ROCK-II
Locus ID 9475
Cytogenetics 2p25.1
Summary The protein encoded by this gene is a serine/threonine kinase that regulates cytokinesis, smooth muscle contraction, the formation of actin stress fibers and focal adhesions, and the activation of the c-fos serum response element. This protein, which is an isozyme of ROCK1 is a target for the small GTPase Rho. [provided by RefSeq, Jul 2008]
Protein Families Druggable Genome, Protein Kinase
Protein Pathways Axon guidance, Chemokine signaling pathway, Focal adhesion, Leukocyte transendothelial migration, Pathogenic Escherichia coli infection, Regulation of actin cytoskeleton, TGF-beta signaling pathway, Vascular smooth muscle contraction, Wnt signaling pathway
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Documents

Other Versions

Customer Reviews 
Loading...